GlassScriptPhysician profile
Rebekah Kim
NPI 1447943006
$3,911.76
in general payments reported to CMS, 2019-2025
20 companies · $1,231 in 2025
The $1,231 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $485 · 2024: $2,196 · 2025: $1,231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,812 · Education: $99.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,812.46 |
| Education | $99.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,146.06 | 2023-2025 | |
| Janssen Biotech, INC. | $420.55 | 2024-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $371.22 | 2023-2025 | Xifaxan, Trulance, Plenvu |
| Ardelyx, INC. | $321.59 | 2024-2025 | Ibsrela |
| Qol Medical, LLC | $285.70 | 2023-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $212.96 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $201.63 | 2023-2025 | Entyvio |
| Phathom Pharmaceuticals, INC. | $155.68 | 2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $137.29 | 2023-2024 | Dupixent |
| Gilead Sciences, INC. | $123.16 | 2025 | Vemlidy |
| E.R. Squibb & Sons, L.L.C. | $113.00 | 2024 | Zeposia |
| Pfizer INC. | $82.94 | 2024-2025 | |
| Celgene Corporation | $80.73 | 2023-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $76.16 | 2024-2025 | Zenpep |
| Ipsen Biopharmaceuticals, INC | $54.19 | 2024-2025 | Iqirvo, Bylvay |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $44.12 | 2024-2025 | Vegzelma, Zymfentra |
| Vivus LLC | $23.83 | 2025 | Qsymia |
| Mallinckrodt Hospital Products INC. | $22.72 | 2025 | Terlivaz |
| Merck Sharp & Dohme LLC | $21.09 | 2024 | Dificid |
| Redhill Biopharma INC. | $17.14 | 2023 | Talicia, Aemcolo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebekah Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.